Skip to main content

Bajaj Healthcare Ltd

Stage 4 · Declining · week 3

As of 16 Oct 2026, Bajaj Healthcare is in Stage 4 — declining, a downtrend, in week 3 (since 25 Sep 2026). It closed at ₹341, 29.1% below its 52-week high and above its 200-day average, which is falling. In Health Care, 40.6% of stocks are in Stage 2.

Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmac… More about the company

₹341.1
+0.68% today
₹1,148 Cr · Small cap
Market Neutral — FadingHealth Care 40.6% in Stage 2-7.4 pts / 20dPharmaceuticals 50.4%-2.5 pts

Pro read

Pro

Our read

Declining — below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is BAJAJHCARE early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
vs 52W High
-29.1%
₹275 lo₹481 hi
29.1% below 52W high — ongoing decline
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 3
1w13w26w
Week 3 — early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
2.1%
200 DMA: ₹334.1 · sloping down
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
1.35x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
→
MA20 flat · -0.2% vs MA50 -1.3%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
+6.2%
3M
-8.8%
6M
-3.0%
YTD
-19.0%
1Y
-27.8%
Sector
Health Care
↓ Peaking
Stage 2%
40.6%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
Sector has 67 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
50.4%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Industry has 57 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Stage Cycle Timeline2023-07-20 → 2026-10-16
S4 19w
S2 21w
S4 17w
S4 31w
2023-07-202026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 1w → S1 8w → S2 11w → S3 10w → S4 19w → S1 6w → S2 11w → S3 5w → S2 21w → S3 11w → S4 17w → S1 4w → S4 31w → S1 10w → S4 3w current
Total tracked: 169 weeks across 15 stage runs.
Scan Membership
Breakout Watch
Latest: 2024-12-06
2 appearances in last 60 days. First seen: 2024-08-14.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding — staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-16S4
Wk 3 · Vol 1.35x
2026-10-15S4
Wk 3 · Vol 2.04x
2026-10-14S4
Wk 3 · Vol 0.83x
2026-10-13S4
Wk 3 · Vol 2.07x
2026-10-12S4
Wk 3 · Vol 1.80x
2026-10-09S4
Wk 2 · Vol 1.02x
2026-10-08S4
Wk 2 · Vol 0.79x
2026-10-07S4
Wk 2 · Vol 0.52x
2026-10-06S4
Wk 2 · Vol 0.59x
2026-10-05S4
Wk 2 · Vol 0.82x
2026-10-01S4
Wk 1 · Vol 0.71x
2026-09-30S4
Wk 1 · Vol 0.43x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹328.9
200 DMA
₹334.1
52W High
₹481
52W Low
₹275
5D Low
₹328.6
Resistance levels (recent highs)
20d High
₹352.7
60d High
₹352.7
120d High
₹386.6
250d High
₹481
Next resistance
+3.4%
to 20d High
P/E (TTM)
45.7
Forward —
ROE
+4.3%
Profit margin +2.6%
Dividend Yield
0.33%
P/B 1.8
About this companyHealth Care· Pharmaceuticals

Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, antihelmintic, iron-chelating agent, anticonvulsant, growth stimulant, non-steroidal anti-inflammatory drugs, antihypertensive, anthelmintics, anti-asthmatic, antioxidant, urinary tract infection, anti-histamine, weight reducing, phlebotropic drug, antimalarial, vitamin c, disinfectant/ antiseptic, stimulant, lipotropic agents, nootropic, vasoprotective/antihemorrhagic, cardiovascular agents, food supplements, anti-anemic, amino acids, antiasthmatic / bronchodilator, nutritional supplement, and minerals. It provides intermediates, such as guanine, 3-methyl xanthine, bromoethyl theophylline, calcium phosphoryl choline chloride, 4-hydrazinobenzoic acid, ticagrelor acetonide, 4,7-dichloroquinolone, 5-[N-ethyl-N-(2-hydroxyethyl)amino]-2-aminopentane, 2-amino -4-hydroxyacetophenone, 8- chloro theophylline, 8 bromo-3-methyl xanthine, 3-methyl-7-(2-butyn-1-yl)-8-bromo xanthine, (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile, 3 – amino – 1 – adamantanol, N – boc -sitagliptin, sitagliptin base, hesperidine, (2,7-dichlori-9H-fluorene), (2-Chloro-1-(2,7- dichlori-9H-fluoren-4-yl)ethanone), (2-(dibutylamino)-1-(2, 7- dichlori-9H-fluoren-4-yl)ethanol), (2-Nitro-4-thiocyanoaniline), 4- (propylthio) benzene -1,2-diamine, methyl [(E)amino(methylsulfanyl)methylidene] carbamate, and (2-phenoxy methane sulphonamide). In addition, the company offers formulations in the form of tablets, capsules, sachets, and vials, as well as impurities. Bajaj HealthCare Limited was incorporated in 1993 and is based in Thane, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.